THE EFFICACY OF FOURTEEN-DAYS ESOMEPRAZOLE AND AMOXICILLIN CONTAINING HIGH DOSE DUAL THERAPY IN THE TREATMENT OF FIRST-LINE ANTI-H. PYLORI THERAPY: A PROSPECTIVE RANDOMIZED TRIAL

被引：0
|
作者：
Huang, Pao-Yuan
Ma, Te-Ling
Tai, Wei-Chen
Liang, Chih-Ming
Wu, Keng-Liang
Chuah, Seng-Kee
机构：
来源：
GASTROENTEROLOGY | 2019年 / 156卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
436
引用
收藏
页码：S89 / S89
页数：1
相关论文
共 50 条
  • [41] High Dose Amoxicillin-Dexlansoprazole Dual Therapy Is A Promising Second Line Rescue Therapy For H. pylori Infection
    Leow, Alex Hwong-Ruey
    Azmi, Ahmad Najib
    Loke, Mun-Fai
    Vadivelu, Jamuna
    Goh, Khean Lee
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 128 - 128
  • [42] Efficacy of 7-day high dose esomeprazole-based triple therapy versus 7-day standard dose non-esomeprazole-based triple therapy for first-line treatment of Helicobacter pylori infection
    Lee, Y.
    Kim, S.
    Park, M.
    Park, S.
    Moon, W.
    Kim, J.
    Jung, K.
    Song, J.
    HELICOBACTER, 2017, 22
  • [43] Efficacy of 7-day high dose esomeprazole-based triple therapy versus 7-day standard dose non-esomeprazole-based triple therapy for first-line treatment of Helicobacter pylori infection
    Heo, Jae Joon
    Kim, Sung Eun
    Park, Moo In
    Park, Seun Ja
    Moon, Won
    Kim, Jae Hyun
    Jung, Kyoungwon
    Song, Jiyun
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 : 91 - 91
  • [44] 14-Day High-Dose Amoxicillin- and Metronidazole-Containing Triple Therapy With or Without Bismuth as First-Line Helicobacter pylori Treatment
    Luo, Laisheng
    Ji, Yingjie
    Yu, Lou
    Huang, Yu
    Liang, Xiao
    Graham, David Y.
    Lu, Hong
    DIGESTIVE DISEASES AND SCIENCES, 2020, 65 (12) : 3639 - 3646
  • [45] 14-Day High-Dose Amoxicillin- and Metronidazole-Containing Triple Therapy With or Without Bismuth as First-Line Helicobacter pylori Treatment
    Laisheng Luo
    Yingjie Ji
    Lou Yu
    Yu Huang
    Xiao Liang
    David Y. Graham
    Hong Lu
    Digestive Diseases and Sciences, 2020, 65 : 3639 - 3646
  • [46] PROSPECTIVE RANDOMIZED STUDY: HIGH-DOSE AMOXICILLIN DUAL THERAPY VERSUS BISMUTH QUADRUPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION.
    Silva, Vitor Macedo
    Capela, Tiago Lima
    Freitas, Marta
    Carvalho, Pedro Boal
    Magalhaes, Joana
    Cotter, Jose
    GASTROENTEROLOGY, 2023, 164 (06) : S379 - S379
  • [47] Randomized trial for comparison of esomeprazole and rabeprazole in the first-line eradication therapy for Helicobacter pylori infection regarding serum level of pepsinogens
    Shimoyama, Tadashi
    Chinda, Daisuke
    Sawada, Yoshihiko
    Komai, Kazuo
    Sasaki, Yoshio
    Chiba, Hironobu
    Saito, Yoshiharu
    Matsuzaka, Masashi
    Fukuda, Shinsaku
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 66 - 66
  • [48] OPEN-LABEL RANDOMIZED CONTROLLED TRIAL OF VONOPRAZAN AND ESOMEPRAZOLE IN FIRST-LINE TRIPLE THERAPY AGAINST HELICOBACTER PYLORI INFECTION
    Tamaki, Hiroyuki
    Morita, Masahiro
    Noda, Teruyo
    Izuta, Masako
    Kubo, Atsushi
    Ogawa, Chikara
    Matsunaka, Toshihiro
    Shibatoge, Mitsushige
    GASTROENTEROLOGY, 2017, 152 (05) : S248 - S248
  • [49] Randomized Trial Comparing Esomeprazole and Rabeprazole in First-line Eradication Therapy for Helicobacter pylori Infection based on the Serum Levels of Pepsinogens
    Shimoyama, Tadashi
    Chinda, Daisuke
    Sawada, Yoshihiko
    Komai, Kazuo
    Chiba, Hironobu
    Saito, Yoshiharu
    Sasaki, Yoshio
    Matsuzaka, Masashi
    Fukuda, Shinsaku
    INTERNAL MEDICINE, 2017, 56 (13) : 1621 - 1627
  • [50] BOTH 14-DAY VONOPRAZAN TRIPLE THERAPY AND 14-DAY RABEPRAZOLE REVERSE HYBRID THERAPY ARE SUPERIOR TO 14-DAY VONOPRAZAN HIGH-DOSE DUAL THERAPY FOR THE FIRST-LINE ANTI-H. PYLORI TREATMENT IN POPULATION WITH HIGH RATES OF ANTIBIOTIC RESISTANCE
    Hsu, Ping-I
    Shih, Chih-An
    Chen, Chien-Lin
    Chuah, Seng-Kee
    Yang, Jyh-Chin
    Wu, Deng-Chyang
    GASTROENTEROLOGY, 2024, 166 (05) : S431 - S431
12345